News & Updates
Filter by Specialty:
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023Garlic vegetable intake prevents gastric cancer
Greater dietary intake of allium vegetables, particularly garlic, provides a protective benefit against the development of gastric cancer (GC), suggests a study. This association is independent from vitamin or garlic supplementation.
Garlic vegetable intake prevents gastric cancer
13 Mar 2023Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
13 Mar 2023Weight status influences urinary function recovery after radical prostatectomy
Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.
Weight status influences urinary function recovery after radical prostatectomy
10 Mar 2023Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
10 Mar 2023mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
10 Mar 2023Gene links breast cancer to stress, circadian disruption
Two researchers from the Philippines have discovered a gene the connects breast cancer development to stress and body clock disruption. In a recent study, they have shown the mechanism behind hormone and circadian regulation of the tumour-suppressor gene, Krüppel-like factor 9 (KLF9), and its effect on breast cancer progression.